120
Participants
Start Date
February 17, 2021
Primary Completion Date
March 31, 2024
Study Completion Date
December 31, 2024
Evolocumab
Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infuser (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference.
Statins (Cardiovascular Agents)
Previously prescribed statin therapy.
RECRUITING
Brigham and Women's Hospital, Boston
Collaborators (1)
Amgen
INDUSTRY
Brigham and Women's Hospital
OTHER